Analystreport

Esperion Therapeutics Inc (NASDAQ: ESPR) had its price target raised by analysts at Citigroup Inc from $46.00 to $56.00. They now have a "buy" rating on the stock.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com